SAN FRANCISCO, Jan. 10 - Norrie Russell, CEO of Lynx Therapeutics, wants to put a proteomics machine on every desktop.
"The foundation technology for proteomics is gel electrophoresis, which is not sensitive enough, not reproducible, and takes forever to do," Russell said on Thursday at the 20th annual JPMorgan H&Q Healthcare Conference, which ended today.
"[Our] philosophy is to decentralize proteomics," he said. "The challenge to the engineers: make it [sit] on a desktop, inexpensive, and easy to use. Every laboratory can have one of these."
Lynx's Protein ProFiler, a 2-D solution-phase separation technology using a micro-channel glass plate, is 12 to 18 months away from coming to market, Russell said.
Except for one thing: the company needs a development partner.
"[We're looking for] someone who already makes instruments," Russell explained.
Russell would not reveal names of possible partners for the marketing and distributing deal, though he said it would be a company such as Agilent or Applied Biosystems. "These kind of guys," said Russell.
Russell did name names in another deal: Celera will be including Lynx's gene expression data on the Celera Discovery System within the next two months, said Russell. Lynx's database contains 54 million data points from 30 samples of normal human tissue, he said.
Russell would not reveal the financial terms of the agreement.